Eli Lilly (LLY)
(Delayed Data from NYSE)
$887.16 USD
+1.61 (0.18%)
Updated Oct 4, 2024 04:00 PM ET
After-Market: $884.12 -3.04 (-0.34%) 7:58 PM ET
1-Strong Buy of 5 1
F Value F Growth A Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$887.16 USD
+1.61 (0.18%)
Updated Oct 4, 2024 04:00 PM ET
After-Market: $884.12 -3.04 (-0.34%) 7:58 PM ET
1-Strong Buy of 5 1
F Value F Growth A Momentum F VGM
Zacks News
Should Invesco Large Cap Growth ETF (PWB) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for PWB
Should You Invest in the iShares U.S. Healthcare ETF (IYH)?
by Zacks Equity Research
Sector ETF report for IYH
Lilly (LLY) to Build $2.5B Plant to Meet Increased Drug Demand
by Zacks Equity Research
Through this expansion, Eli Lilly (LLY) intends to expand its global manufacturing footprint to support the rising demand for its diabetes and obesity portfolio.
Investors Heavily Search Eli Lilly and Company (LLY): Here is What You Need to Know
by Zacks Equity Research
Lilly (LLY) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Billionaires Bullish on Big Tech: ETFs in Focus
by Sanghamitra Saha
The latest 13-F filings of billionaires indicate that most are still bullish on big techs.
13F Rundown: Tepper, Buffett, Druckenmiller
by Andrew Rocco
Stock Strategist Andrew Rocco divulges valuable insights from the world's best and brightest investors.
Is Goldman Sachs Equal Weight U.S. Large Cap Equity ETF (GSEW) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for GSEW
Catalent (CTLT) Up on Encouraging Pre-Filled Syringe Potential
by Zacks Equity Research
Catalent (CTLT) expects the demand for its pre-filled syringes to improve going forward. The company anticipates the majority of its pre-filled syringe production capacity to be booked until fiscal 2026.
Should SPDR MSCI USA StrategicFactors ETF (QUS) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for QUS
Is First Trust Capital Strength ETF (FTCS) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for FTCS
Zacks Industry Outlook Highlights Eli Lilly, Novo Nordisk, J&J and AbbVie
by Zacks Equity Research
Eli Lilly, Novo Nordisk, J&J and AbbVie are part of the Zacks Industry Outlook article.
Novo Nordisk's (NVO) Wegovy Positive in Cardiovascular Study
by Zacks Equity Research
Novo Nordisk's (NVO) obesity drug Wegovy shows potential in cardiovascular study beyond the benefits of associated weight loss.
4 Large Drug Stocks Likely to Sail Through Industry Woes
by Kinjel Shah
Drug, biotech companies are likely to see significant innovation. In the Large-Cap Pharmaceuticals industry, Eli Lilly (LLY), Novo Nordisk (NVO), J&J (JNJ) and AbbVie (ABBV) are worth retaining in your portfolio.
Should You Invest in the Vanguard Health Care ETF (VHT)?
by Zacks Equity Research
Sector ETF report for VHT
AstraZeneca (AZN) Buys Global Rights to Oral Obesity Candidate
by Zacks Equity Research
To cash in on the rising demand for obesity drugs, AstraZeneca (AZN) in-licenses exclusive rights to ECC5004, a novel oral GLP-1RA therapy, from private Chinese biotech Eccogene.
Beam Therapeutics (BEAM) Q3 Earnings & Revenues Beat Estimates
by Zacks Equity Research
Beam Therapeutics' (BEAM) third-quarter 2023 earnings and revenues surpass expectations. The company focuses on developing genome-editing candidate, BEAM-101.
Zacks Earnings Trends Highlights: Pfizer, Eli Lilly, General Motors and Tesla
by Zacks Equity Research
Pfizer, Eli Lilly, General Motors and Tesla have been highlighted in this Earnings Trends article.
Earnings Estimates Come Under Pressure
by Sheraz Mian
While Q3 results have been better than expected, there is a notable acceleration in negative estimate revisions over the last few weeks, contrasting the largely favorable revisions trend of the preceding six months.
Earnings Estimates Come Under Pressure
by Sheraz Mian
While Q3 results have been better than expected, there is a notable acceleration in negative estimate revisions over the last few weeks, contrasting the largely favorable revisions trend of the preceding six months.
Nektar Therapeutics (NKTR) Incurs Wider-Than-Expected Q3 Loss
by Zacks Equity Research
Nektar (NKTR) misses third-quarter estimates for the bottom line but beats the same for the top line.
Eli Lilly and Company (LLY) is Attracting Investor Attention: Here is What You Should Know
by Zacks Equity Research
Lilly (LLY) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Eli Lilly Beats on Q3 Earnings: ETFs to Buy
by Sweta Killa
Eli Lilly (LLY) posted robust third-quarter 2023 earnings results, beating estimates on both the top and bottom lines. Its Mounjaro anti-obesity drug continued its robust performance.
Company News for Nov 03, 2023
by Zacks Equity Research
Companies In The Article: LLY, SBUX, SHOP, CYBR
Eli Lilly (LLY) Q3 Earnings & Sales Top, EPS View Cut, Stock Up
by Zacks Equity Research
Eli Lilly (LLY) beats third-quarter estimates for earnings as well as sales. It cut its earnings guidance for 2023 on charges related to acquisitions and collaboration deals.
Compared to Estimates, Lilly (LLY) Q3 Earnings: A Look at Key Metrics
by Zacks Equity Research
While the top- and bottom-line numbers for Lilly (LLY) give a sense of how the business performed in the quarter ended September 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.